Allergy Therapeutics – investor update video

11th July 2019 | Allergy Therapeutics plc

Allergy Therapeutics this morning provided a trading update which showed earnings ahead of expectations. Sales have grown by 8% to £73.7m. At the period end, AGY had cash in the bank of£27.4m which includes c.£6m in the litigation settlement against Inflamax regarding a clinical trial, which AGY alleged was poorly run by Inflamax.

Allergy is listed on London’s AIM stock exhchange with the ticker LSE: AGY. Finance Director Nick Wykeman discusses the Company’s recent performance in the video below.

Allergy Therapeutics – investor update video

Allergy Therapeutics Investors Video

CEO Manuel Llobet on Five Minute pitch TV updating investors on the progress of their allergy vaccines

Click here to view Allergy Therapeutics investor video